Literature DB >> 34279478

Echocardiographic Assessment of Right Ventricular-Arterial Coupling in Predicting Prognosis of Pulmonary Arterial Hypertension Patients.

Remigiusz Kazimierczyk1, Ewelina Kazimierczyk1, Malgorzata Knapp1, Bozena Sobkowicz1, Lukasz A Malek2, Piotr Blaszczak3, Katarzyna Ptaszynska-Kopczynska1, Ryszard Grzywna3, Karol A Kaminski1,4.   

Abstract

In response to an increased afterload in pulmonary arterial hypertension (PAH), the right ventricle (RV) adapts by remodeling and increasing contractility. The idea of coupling refers to maintaining a relatively constant relationship between ventricular contractility and afterload. Twenty-eight stable PAH patients (mean age 49.5 ± 15.5 years) were enrolled into the study. The follow-up time of this study was 58 months, and the combined endpoint (CEP) was defined as death or clinical deterioration. We used echo TAPSE as a surrogate of RV contractility and estimated systolic pulmonary artery pressure (sPAP) reflecting RV afterload. Ventricular-arterial coupling was evaluated by the ratio between these two parameters (TAPSE/sPAP). In the PAH group, the mean pulmonary artery pressure (mPAP) was 47.29 ± 15.3 mmHg. The mean echo-estimated TAPSE/sPAP was 0.34 ± 0.19 mm/mmHg and was comparable in value and prognostic usefulness to the parameter derived from magnetic resonance and catheterization (ROC analysis). Patients who had CEP (n = 21) had a significantly higher mPAP (53.11 ± 17.11 mmHg vs. 34.86 ± 8.49 mmHg, p = 0.03) and lower TAPSE/sPAP (0.30 ± 0.21 vs. 0.43 ± 0.23, p = 0.04). Patients with a TAPSE/sPAP lower than 0.25 mm/mmHg had worse prognosis, with log-rank test p = 0.001. the echocardiographic estimation of TAPSE/sPAP offers an easy, reliable, non-invasive prognostic parameter for the comprehensive assessment of hemodynamic adaptation in PAH patients.

Entities:  

Keywords:  coupling; echocardiography; prognosis; pulmonary arterial hypertension; right ventricle

Year:  2021        PMID: 34279478     DOI: 10.3390/jcm10132995

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  3 in total

1.  Interleukin-33 and soluble suppression of tumorigenicity 2 in scleroderma cardiac involvement.

Authors:  Francesco Iannazzo; Chiara Pellicano; Amalia Colalillo; Cesarina Ramaccini; Antonella Romaniello; Antonietta Gigante; Edoardo Rosato
Journal:  Clin Exp Med       Date:  2022-07-25       Impact factor: 5.057

2.  Carbon Monoxide Diffusion Capacity as a Severity Marker in Pulmonary Hypertension.

Authors:  Eleni Diamanti; Vasiliki Karava; Patrick Yerly; John David Aubert
Journal:  J Clin Med       Date:  2021-12-27       Impact factor: 4.241

3.  Mean Velocity of the Pulmonary Artery as a Clinically Relevant Prognostic Indicator in Patients with Heart Failure with Preserved Ejection Fraction.

Authors:  Blanca Trejo-Velasco; Ignacio Cruz-González; Manuel Barreiro-Pérez; Elena Díaz-Peláez; Pilar García-González; Ana Martín-García; Rocío Eiros; Soraya Merchán-Gómez; Candelas Pérez Del Villar; Oscar Fabregat-Andrés; Francisco Ridocci-Soriano; Pedro L Sánchez
Journal:  J Clin Med       Date:  2022-01-19       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.